251 related articles for article (PubMed ID: 28726491)
1. Interview with Thomas Powles: The use of durvalumab in urothelial cancer - the latest strides in immuno-oncology.
Powles T
Future Oncol; 2017 Aug; 13(18):1581-1583. PubMed ID: 28726491
[TBL] [Abstract][Full Text] [Related]
2. Durvalumab in non-small-cell lung cancer patients: current developments.
Mezquita L; Planchard D
Future Oncol; 2018 Feb; 14(3):205-222. PubMed ID: 29140105
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes.
Rodriguez-Vida A; Perez-Gracia JL; Bellmunt J
Clin Cancer Res; 2018 Dec; 24(24):6115-6124. PubMed ID: 29991503
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for metastatic urothelial carcinoma: status quo and the future.
Necchi A; Rink M; Giannatempo P; Raggi D; Xylinas E
Curr Opin Urol; 2018 Jan; 28(1):1-7. PubMed ID: 29028766
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for immunotherapy in urological cancers.
Gust KM; Resch I; D'Andrea D
Curr Opin Urol; 2018 Jan; 28(1):25-28. PubMed ID: 29120910
[TBL] [Abstract][Full Text] [Related]
6. Role of Targeted Therapies in Management of Metastatic Urothelial Cancer in the Era of Immunotherapy.
Grivas P; Yu EY
Curr Treat Options Oncol; 2019 Jun; 20(8):67. PubMed ID: 31254108
[TBL] [Abstract][Full Text] [Related]
7. Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.
Lavoie JM; Black PC; Eigl BJ
J Urol; 2019 Jul; 202(1):49-56. PubMed ID: 30730407
[TBL] [Abstract][Full Text] [Related]
8. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.
Powles T; Carroll D; Chowdhury S; Gravis G; Joly F; Carles J; Fléchon A; Maroto P; Petrylak D; Rolland F; Cook N; Balar AV; Sridhar SS; Galsky MD; Grivas P; Ravaud A; Jones R; Cosaert J; Hodgson D; Kozarewa I; Mather R; McEwen R; Mercier F; Landers D
Nat Med; 2021 May; 27(5):793-801. PubMed ID: 33941921
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.
Powles T; Smith K; Stenzl A; Bedke J
Eur Urol; 2017 Oct; 72(4):477-481. PubMed ID: 28413128
[TBL] [Abstract][Full Text] [Related]
10. [Renaissance of immuno-oncology for urological tumors : Current status].
Grimm MO; Winkler Y; Fetter I; Oppel-Heuchel H
Urologe A; 2016 May; 55(5):621-6. PubMed ID: 27119960
[TBL] [Abstract][Full Text] [Related]
11. Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go.
Gevaert T; Cimadamore A; Eckstein M; Scarpelli M; Lopez-Beltran A; Cheng L; Montironi R
Future Oncol; 2019 Jul; 15(19):2199-2202. PubMed ID: 31213082
[No Abstract] [Full Text] [Related]
12. Pembrolizumab in the treatment of advanced urothelial cancer.
Lundgren KT; Farina MS; Bellmunt J
Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for metastatic urothelial carcinoma: putting the brakes on releasing the brake.
Zibelman M; Plimack ER
Immunotherapy; 2018 Mar; 10(6):423-425. PubMed ID: 29562856
[No Abstract] [Full Text] [Related]
15. Cancer Immunotherapy: The Dawn of Antibody Cocktails.
Marrocco I; Romaniello D; Yarden Y
Methods Mol Biol; 2019; 1904():11-51. PubMed ID: 30539465
[TBL] [Abstract][Full Text] [Related]
16. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
Santana-Davila R; Chow LQ
Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
[No Abstract] [Full Text] [Related]
17. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
18. The importance for immunoregulation for long-term cancer control.
Fusi A; Dalgleish A
Future Oncol; 2017 Aug; 13(18):1619-1632. PubMed ID: 28776411
[TBL] [Abstract][Full Text] [Related]
19. Olaparib recommendations for ovarian cancer patients.
Johnson P; Westcott G
Future Oncol; 2016 Jan; 12(2):149-51. PubMed ID: 26616222
[TBL] [Abstract][Full Text] [Related]
20. Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.
Yan Y; Kumar AB; Finnes H; Markovic SN; Park S; Dronca RS; Dong H
Front Immunol; 2018; 9():1739. PubMed ID: 30100909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]